« Previous
Next »
Titles
- A sense of déjà vu: the debate surrounding state biosimilar substitution laws1
- Assessing user fees under the Generic Drug User Fee Amendments of 20171
- Biologics in perspective: the case for generic biologic drugs1
- Generic drug user fees: application review times declined, but FDA should develop a plan for administering its unobligated user fees : report to the Chairman, Committee on Health, Education, Labor, and Pensions, U.S. Senate1
- Generic drugs: Stakeholder views on improving FDA’s information on patents : report to congressional committees1
- Generic drugs: your Rx for savings1
- Getting to the root of high prescription drug prices: drivers and potential solutions1
- Medicare Part D1
- Medication literacy series. Generic drugs1
- Price decreases for widely used generic drugs slow in 2017 after two years of substantial price drops1
- Rx Watchdog report: comparative measures of price change for prescription drugs and other goods1
- Rx price watch report: price growth for brand name and specialty drugs more than offset price decrease for generic drugs1
- Rx price watch report: trends in retail prices of generic prescription drugs widely used by Medicare beneficiaries : 2005 to 20091
- Rx price watch report: trends in retail prices of specialty prescription drugs widely used by Medicare beneficiaries : 2005 to 20091
- Rx watchdog report trends in manufacturer prices of generic prescription drugs used by Medicare beneficiaries 2003 to 20071
- Rx watchdog report: brand name drug prices continue to climb despite low general inflation rate1
- Rx watchdog report: trends in manufacturer prices of prescription drugs used by Medicare beneficiaries, 2008 year-end update1
- Snapshots of recent state initiatives in Medicaid prescription drug cost control1
- The effect of Medicare Part D on evergreening, generic entry, and drug prices1
- Trends in P2Y12 receptor inhibitor use and adherence after percutaneous coronary intervention, 2008-20161